Back to Search

INTREPId (INTermediate Risk Erection PreservatIon Trial): A Randomized Trial of Radiation Therapy and Darolutamide for Prostate Cancer

  • Protocol Number: 202010193
  • Principal Investigator: Michalski, Jeff
  • Cancer Types: GU: Bladder, Kidney, Prostate, Testicular

Learn more about this study at: clinicaltrials.gov

For more information on this trial, contact us here:

Phone
800-600-3606
Email
[email protected]

Brief Summary

This research study is comparing the use of a new form of hormonal therapy used with radiation as a possible treatment for intermediate risk prostate cancer. More specifically, this research would help determine whether this new form of hormonal therapy is as effective as the standard hormone therapy while also preserving erectile function.

Protocol Interventions

Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide